Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Scicinski

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.
Redox Biology|July 13, 2015
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001Jan Scicinski, Bryan Oronsky, Shoucheng Ning, et al.
Oncotarget|August 18, 2015
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001Shoucheng Ning, Thillai Veerapazham Sekar, Jan Scicinski, et al.
Case Reports in Oncology|July 13, 2016
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum DoubletsCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 16, 2012
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agentJan Scicinski, Bryan Oronsky, Michael Taylor, et al.
Oncotarget|December 20, 2017
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumorsNatarajan Raghunand, Jan Scicinski, Gerald P Guntle, et al.
Bioanalysis|May 9, 2014
Development of methods for the bioanalysis of RRx-001 and metabolitesJan Scicinski, Bryan Oronsky, Vance Cooper, et al.
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Journal of Pharmaceutical Sciences|April 5, 2012
Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculationGary Eichenbaum, C-P Hsu, Vangala Subrahmanyam, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivativesPaul G Wyatt, Michael J Allen, Josie Chilcott, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.
Redox Biology|July 13, 2015
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001Jan Scicinski, Bryan Oronsky, Shoucheng Ning, et al.
Oncotarget|August 18, 2015
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001Shoucheng Ning, Thillai Veerapazham Sekar, Jan Scicinski, et al.
Case Reports in Oncology|July 13, 2016
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum DoubletsCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 16, 2012
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agentJan Scicinski, Bryan Oronsky, Michael Taylor, et al.
Oncotarget|December 20, 2017
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumorsNatarajan Raghunand, Jan Scicinski, Gerald P Guntle, et al.
Bioanalysis|May 9, 2014
Development of methods for the bioanalysis of RRx-001 and metabolitesJan Scicinski, Bryan Oronsky, Vance Cooper, et al.
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Journal of Pharmaceutical Sciences|April 5, 2012
Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculationGary Eichenbaum, C-P Hsu, Vangala Subrahmanyam, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivativesPaul G Wyatt, Michael J Allen, Josie Chilcott, et al.
Pageof 5